<DOC>
	<DOCNO>NCT01970072</DOCNO>
	<brief_summary>The purpose study evaluate compare Pharmacokinetics/Pharmacodynamics safety Remimazolam Tosylate midazolam healthy volunteer</brief_summary>
	<brief_title>A Phase Ⅰa Study Remimazolam Tosylate Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy male female Weight range 50 100 kg inclusive Body mass index ( BMI ) 18 26 kg/m2 Has know sensitivity benzodiazepine , flumazenil , anesthetic agent , medical condition agent contraindicate With evidence uncontrolled renal , hepatic , central nervous system , respiratory , cardiovascular , metabolic dysfunction , opinion investigator medical monitor Has know suspect history alcoholism drug abuse misuse within 6 month Screening evidence tolerance physical dependence dose study drug With history laboratory result show presence hepatitis B surface antigen ( HBs Ag ) , hepatitis C antibody ( HCV Ab ) , human immunodeficiency virus ( HIV ) Pregnant , lactate Mallampati score ≥3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Remimazolam Tosylate</keyword>
	<keyword>Phase Ⅰ study</keyword>
	<keyword>Health</keyword>
</DOC>